Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7,265 INR | -2.69% | -4.10% | +37.86% |
04-12 | INDIA STOCKS-Financials drag Indian shares, hit by fading US rate cut hopes | RE |
03-31 | Neuland Laboratories Limited Announces Resignation of P.V. Maiya as Director | CI |
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 64% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.99 times its estimated earnings per share for the ongoing year.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+37.86% | 1.16B | - | ||
+31.52% | 662B | C+ | ||
+21.96% | 546B | B | ||
-5.21% | 359B | C+ | ||
+17.02% | 323B | B- | ||
+5.01% | 289B | C+ | ||
+13.68% | 234B | B+ | ||
+3.81% | 198B | B- | ||
-10.63% | 194B | A+ | ||
+3.98% | 167B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NEULANDLAB Stock
- Ratings Neuland Laboratories Limited